Pharmaceutical giant,
It added that the analysis of vaccine also revealed that it is effective on people of all ages, races and ethnicities and caused no serious safety concerns.
The companies said they would now apply for authorisation for emergency use of the jab in the United States.The findings are based on two doses given to more than 41,000 people around the world.
Last week,
Yesterday's data from the companies suggested that the vaccine is 95 per cent effective, based on 170 cases of Covid-19 developing in volunteers - just eight were in the group given the vaccine, suggesting it offers good protection.
The rest of the cases were in the placebo group given a dummy jab.
Although the full trial data has yet to be published, the companies said there have been no serious safety concerns. But they did notice headaches and fatigue in about two per cent of volunteers given the vaccine.
In the trial, 42 per cent of all participants are from diverse ethnic backgrounds and 41per cent are aged between 56 and 85 years old.
The trial, which is testing people at 150 sites in the US,
The companies behind it expect to produce up to 50 million doses of the vaccine this year and up to 1.3 billion doses by the end of 2021.
The
It has also ordered 100 million doses of the Oxford-AstraZeneca vaccine, which is planning to release data from its phase three trial soon.
There are hundreds of vaccines in development around the world, and about a dozen in the final stages of testing, known as phase three.
The first two to show any results - made by Pfizer-BioNTech and
Antibodies and T-cells are then made by the body to fight the coronavirus.
There are logistical challenges with these kinds of vaccines, namely the need to store them at ultra-cold temperatures.
The
Copyright This Day. Distributed by AllAfrica Global Media (allAfrica.com)., source